Trials / Unknown
UnknownNCT03954756
Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
Phase II Clinical Study of the Combination of Apatinib and PD1 in Treating Advanced Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced Gastric Cancer.
Detailed description
Patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib and PD1 | 1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal 2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks. |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
- First posted
- 2019-05-17
- Last updated
- 2019-05-17
Source: ClinicalTrials.gov record NCT03954756. Inclusion in this directory is not an endorsement.